11-57614474-C-T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The NM_000062.3(SERPING1):c.1396C>T(p.Arg466Cys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R466L) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000062.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SERPING1 | NM_000062.3 | c.1396C>T | p.Arg466Cys | missense_variant | 8/8 | ENST00000278407.9 | NP_000053.2 | |
SERPING1 | NM_001032295.2 | c.1396C>T | p.Arg466Cys | missense_variant | 7/7 | NP_001027466.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SERPING1 | ENST00000278407.9 | c.1396C>T | p.Arg466Cys | missense_variant | 8/8 | 1 | NM_000062.3 | ENSP00000278407 | P2 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not provided Pathogenic:4Other:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Dec 13, 2022 | Not observed in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 27116602, 23437219, 23123409, 24456027, 26154504, 26751894, 26535898, 2563376, 18758157, 18586324, 25258140, 15971231, 22994404, 26809362, 26812872, 27826968, 21864911, 28302171, 29753808, 30556912, 32896191) - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 09, 2023 | This variant disrupts the p.Arg466 amino acid residue in SERPING1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 2563376, 23437219, 30556912). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on SERPING1 protein function. This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 466 of the SERPING1 protein (p.Arg466Cys). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with hereditary angioedema (PMID: 2563376, 18586324, 18758157, 23437219, 26812872, 30556912). It has also been observed to segregate with disease in related individuals. This variant is also known as p.Arg444Cys. ClinVar contains an entry for this variant (Variation ID: 3947). - |
Pathogenic, criteria provided, single submitter | clinical testing | Clinical Genetics Laboratory, Skane University Hospital Lund | Mar 19, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Sep 01, 2023 | SERPING1: PM1, PM2, PM5, PS4:Moderate, PP1, PP4 - |
not provided, no classification provided | literature only | UniProtKB/Swiss-Prot | - | - - |
Hereditary angioedema type 1 Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | Dec 12, 2018 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Department of Immunology and Histocompatibility, University of Thessaly | - | The c.1396C>T (p.Arg466Cys) variant has been previously reported in association with with hereditary angioedema in the literature (Skriver et al., 1989; Freiberger et al., 2002; Roche et al., 2005; Gosswein et al., 2008; Pappalardo et al., 2008; Lopez-Lera et al., 2011; Xu et al., 2012; Cagini et al., 2016, Loules et al., 2018), in HAE database (http://hae.enzim.hu/detail.php?id=43) and in ClinVar database. The variant has not been detected in approximately 120000 individuals of the Exome Aggregation Consortium (ExAC) database, indicating that it is not a common variant. It was detected by our laboratory in 4 C1-INH-HAE Type II patients of a Greek family (2 male and 2 female) and 1 unrelated female patient with HAE type II and no family history. Skriver et al., 1989 presented conflicting observations about the inhibitory activity of C1-INH and consequently about the pathogenicity of the mutation. Missense variants changing the same residue [c.1397G>A (p.Arg466His), c.1396C>A (p.Arg466Ser), c.1396C>G (p.Arg466Gly), c.1397G>C (p.Arg466Pro), c.1397G>T (p.Arg466Leu)] and in nearby residues [c.1394C>T (p.Ala465Val)] have been previously reported in association with angioneurotic edema. Taking all the above into account and according to ACMG Guidelines, 2015 (Criteria: PS1, PS4, PM2, PP1, PP2, PP4), the variant is considered pathogenic. - |
Hereditary C1 esterase inhibitor deficiency - dysfunctional factor Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Jun 11, 2021 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at